.svg){kind=icon}
View all IQVIA events
Join us at the world's premier oncology event.
ASCO's robust scientific and education programs will be held online again this year. We look forward to connecting with customers and colleagues virtually in June.
Imagine a world in which you move oncology innovation forward by bringing treatments to patients faster and more precisely than ever before. By making intelligent connections, IQVIA brings together R&D, real world and commercial solutions that help you connect the dots, capture best practice, and be at the forefront of today's oncology development.
Visit our online exhibit at ASCO to learn how our specialized oncology teams with IQVIA, IQVIA Biotech and Q2 Solutions can support your study from clinical to commercial.
We hope to connect with you at the 2021 ASCO Annual Meeting!
Click here for more information.
ASCO's robust scientific and education programs will be held online again this year. We look forward to connecting with customers and colleagues virtually in June.
Imagine a world in which you move oncology innovation forward by bringing treatments to patients faster and more precisely than ever before. By making intelligent connections, IQVIA brings together R&D, real world and commercial solutions that help you connect the dots, capture best practice, and be at the forefront of today's oncology development.
Visit our online exhibit at ASCO to learn how our specialized oncology teams with IQVIA, IQVIA Biotech and Q2 Solutions can support your study from clinical to commercial.
We hope to connect with you at the 2021 ASCO Annual Meeting!
Click here for more information.
IQVIA publications in ASCO21 virtual scientific program
The American Society of Clinical Oncology 2021 Annual Meeting features 21 abstracts from IQVIA demonstrating Connected Intelligence solutions spanning precision medicine, immuno-oncology trials, and real world insights during a global pandemic.
Featured Abstracts
Abstract
Evaluating real-world overall survival (rwOS) across oncology data sources: Friends of Cancer Research non-small cell lung cancer pilot study.
Publication-Only Abstracts: Health Services Research and Quality Improvement
Abstract
Advanced tumor progression detection by leveraging EHR based convolutional neural network boosting approaches.
Publication-Only Abstracts: Care Delivery and Regulatory Policy
Abstract
Why are oncologists not testing all NSCLC patients for biomarkers in the U.S. market?
Publication-Only Abstracts: Lung Cancer—Non-Small Cell Metastatic
See below for more ASCO21 abstracts from IQVIA authors.
Breast cancer survivorship and level of institutional involvement utilizing integrative oncology.
Publication-Only Abstracts: Health Services Research and Quality Improvement
View Abstract
Awareness, perceptions, and usage of whole person integrative oncology practices: Similarities and differences between breast cancer patients and oncologists.
Publication-Only Abstracts: Symptoms and Survivorship
View Abstract
Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
Oral Abstract Session: Breast Cancer—Metastatic
View Abstract
A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.
Poster Session: Developmental Therapeutics—Immunotherapy
View Abstract
An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.
Poster Session: Gynecologic Cancer
View Abstract
Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.
Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
View Abstract
Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥50%: Results from EMPOWER-Lung 1 study.
Poster Session: Lung Cancer—Non-Small Cell Metastatic
View Abstract
Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.
Poster Session: Melanoma/Skin Cancers
View Abstract
The impact of cancer-related diarrhea on changes in cancer therapy patterns.
Poster Session: Symptoms and Survivorship
View Abstract
Oncology clinical research landscape in Middle East and North Africa (MENA) region: Challenges and proposed solutions.
Publication-Only Abstracts: Care Delivery and Regulatory Policy
View Abstract
OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling—The use of a common data model and shared analytical methods.
Publication-Only Abstracts: Care Delivery and Regulatory Policy
View Abstract
Phase I study of BJ-001, a tumor-targeting interleukin-15 fusion protein, in patients with solid tumor.
Publication-Only Abstracts: Developmental Therapeutics—Immunotherapy
View Abstract
Cost-effectiveness of atezolizumab monotherapy versus pembrolizumab monotherapy for first-line (1L) treatment of metastatic non-small cell lung cancer (mNSCLC).
Publication-Only Abstracts: Health Services Research and Quality Improvement
View Abstract
Characterizing unplanned resource utilization associated with cancer-related diarrhea.
Publication-Only Abstracts: Health Services Research and Quality Improvement
View Abstract
Healthcare utilization and costs associated with cancer-related diarrhea.
Publication-Only Abstracts: Health Services Research and Quality Improvement
View Abstract
Incidence of pneumonitis among limited-stage small cell lung cancer patients exposed to concurrent chemoradiation: A systematic literature review and meta-analysis.
Publication-Only Abstracts: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
View Abstract
Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A meta-analysis.
Publication-Only Abstracts: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
View Abstract
Psychometric properties of patient reported outcome (PRO) instruments in patients with small cell lung cancer (SCLC) in RESILIENT part 1.
Publication-Only Abstracts: Symptoms and Survivorship